SAT0085 A study on characteristics of rheumatoid arthritis patients achieving depression remission with 6 months of biologic agent treatment
Authors: Y Miwa, N Yajima, T Isozaki, R Takahashi, Y Miura, Y Ikari, M Hatano, T Hayashi, T Kasama, K Sanada
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Approximately 15% of RA patients also suffer from depression, with an odds ratio of 1.42 (95% CI 1.3 - 1.5) compared with healthy people. A previous study reported that biological agents can improve the depressed state associated with RA. Although previous studies have been cross-sectional, there were no reports that analyzed factors that led to depression remission. <h3>Objectives</h3> To examine the relationship between baseline factors and depression remission after six-month biologic agent treatment in rheumatoid arthritis (RA) patients. <h3>Methods</h3> The subjects were 384 RA patients treated with biologic agents. The following patient9s characteristics were investigated: age, gender, number of previous drugs, disease duration, type of biologic agents, baseline steroid dosage, methotrexate dosage and serum matrix metalloproteinase-3 (MMP-3) levels. For evaluation, we used the Simplified Disease Activity Index for RA disease activity; the Health Assessment Questionnaire Disability Index (HAQ-DI) score for activities of daily living; the Short Form-36 for nonspecific health-related quality of life; and Hamilton Depression Rating Scale (HAM-D) scores for depression status. Depression remission was defined by HAM-D≦7 after 6 months of treatment. The subjects were divided into two groups according to the presence or absence of depression, and a retrospective study was performed. <h3>Results</h3> We included 152 patients in the analysis. Two hundred thirty-two patients were excluded due to primary and secondary failure, complications, loss to 6-month follow-up, incomplete data, etc. Compared with a group of RA patients with depression remission (n=124), a group of patients with no depression remission (n=28) had a younger age (p=0.000), female sex (p=0.039), lower serum MMP-3 levels (p=0.021), lower HAQ-DI (p=0.018), lower HAM-D score (p=0.000), and higher Role/Social component summary score of the SF-36 (p=0.009) by univariate analyses. The binominal logistic analyses findings were as follows: younger age (p=0.0045, odd ratio: 0.94, 95% CI: 0.8–0.98), female sex (p=0.021, odd ratio: 0.21, 95% CI: 0.054–0.79), and lower HAM-D scores (p=0.0073, odd ratio: 0.85, 95% CI: 0.76–0.96). <h3>Conclusions</h3> It was suggested that RA patients who are female, younger in age and have lower depression scores at baseline are more likely to achieve depression remission status with the biologic treatment. <h3>Acknowledgements</h3> All Showa University in Rheumatoid Arthritis (ASHURA) group <h3>Disclosure of Interest</h3> Y. Miwa Grant/research support from: Astellas Pharma Inc., Mitsubishi Tanabe Pharma Corporation, Pfizer Japan Inc., Chugai Pharmaceutical Co., Ltd., and Eizai Co., Ltd., Ono Pharma Co., Ltd., N. Yajima: None declared, T. Isozaki: None declared, R. Takahashi: None declared, Y. Miura: None declared, Y. Ikari: None declared, M. Hatano: None declared, T. Hayashi: None declared, T. Kasama Grant/research support from: Mitsubishi Tanabe Pharma Corporation and Pfizer Japan Inc., K. Sanada: None declared